A combination of budesonide and the SH-metabolite I of erdosteine acts synergistically in reducing chemiluminescence during human neutrophil respiratory burst.

摘要: Activated neutrophils can release superoxide anion and nitric oxide (NO), which subsequently combine with each other to yield peroxynitrite anions, powerful harmful oxidants that preferentially mediate the oxidation of thiol groups in proteins non-protein molecules. These play a direct role inflammatory process chronic obstructive pulmonary disease asthma by increasing number macrophages induce self-sustaining phlogogenic loop. Budesonide (BUD) erdosteine (a muco-active drug which, after metabolization, produces an active metabolite (Met I) sulfhydryl group) are both reducing anion, NO peroxynitrite, be administered patients respiratory diseases. The aim this study was investigate possible synergistic vitro effect BUD Met I on chemiluminescence generation during fMLP-stimulated bursts human donor L-arginine, added incubating medium. investigated concentrations ranged from 6 x 10(-8) 1 10(-6) mol/l logarithmic scale significant progressive reduction luminol-amplified (LACL) observed at ranging 2.5 10(-7) mol/l. varied 0.62 10 microg/ml. No changes were 0.62, 1.25, microg/ml, but decrease LACL 5 When two drugs combined, there greater versus single combinations plus 1.25 A further interesting finding combination microg/ml significantly decreased LACL, whereas had no effect, thus indicating possibility extending duration effect. Our findings indicate antioxidant when given together, is interest for counteracting airway phlogosis involved many